On Day Two of 2024's LSX World Congress, we’ll hear about the biotech/biopharma IPO market, the 2024 US Presidential election, and about the future of digital health.
Executives from AstraZeneca, Takeda, Merck, Roche, Johnson & Johnson, Bayer, Teva, Otsuka, and Lilly will all weigh in throughout the day.
With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O
At the LSX (Life Sciences Executive) World Congress in Boston, leaders in biotech, healthtech, and medtech will gather to share trends, insights, and strategies for keeping on top of the va
The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.
Rare diseases are complex, but the need is urgent. Alexion’s Eunice Alvazzi discusses the shared responsibility in achieving access to innovation in rare diseases
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
Optimizing Lead Discovery, Structural Analysis & Preclinical Modeling to Successfully Develop Stable, Effective & Orally Bioavailable Small Molecule RNA Drugs for Robust Translation
Integrate Computational Biology, Generative AI & Machine Learning to Revolutionize Biologics Drug Discovery & Development
